Recruiting at 1 site No phase Chronic Widespread Pain

Chronic Widespread Pain study: Relistor Injectable Product

Official title Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

ClinicalTrials.gov ID: NCT04787848

What this study is testing

What is Relistor Injectable Product?

This is an investigational injectable medicine being studied to see if it helps with chronic widespread pain in people with HIV. It is designed to block opioid receptors in the gut to help relieve constipation caused by opioid pain medicines.

Also referred to as Methylnaltrexone Bromide.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study is looking at how pain signals work. It checks if low pain-relieving chemicals cause extra pain.
Who it's for
You may be able to join if you have HIV and chronic widespread pain.
What's involved
You would take part in tests to check your pain levels. The team will look at your body's pain signals.
Time commitment
The source text does not say how long the study lasts or what visits are needed.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 19 to 65. Healthy volunteers may be eligible.

You may be able to join if

  • Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic
  • Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly...

You likely can't join if

  • All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study
  • Anemia
  • Current or past history of blood disorders which may increase hemolysis
  • Active microbial infections which may alter the quantity or quality of blood inflammatory cells such as monocytes and neutrophils
  • Use of certain medication other than antiretroviral therapy that might conflict with study observations.
  • Systemic rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus).
See the full eligibility criteria
Who can join
  • Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic
  • Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly likely to meet one or more
What rules you out
  • All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study
  • Anemia
  • Current or past history of blood disorders which may increase hemolysis
  • Active microbial infections which may alter the quantity or quality of blood inflammatory cells such as monocytes and neutrophils
  • Use of certain medication other than antiretroviral therapy that might conflict with study observations.
  • Systemic rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus). These rheumatologic conditions will be excluded due to their autoimmune characteristic. .
  • A history of clinically significant surgery in the past year
  • Uncontrolled hypertension (i.e. SBP/DBP of \>150/95) or cardiovascular or peripheral arterial disease.
  • Poorly controlled diabetes (HbA1c \> 8%) for both safety reasons, and because diabetic neuropathy could alter pain perception
  • Neurological disease (e.g. Parkinson's, multiple sclerosis, epilepsy)
  • Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation
  • Any participant deemed to be actively suicidal upon study screening will be escorted to the UAB emergency room and evaluated by the Psychiatry Service
  • Diminished cognitive function that would interfere with understanding of study procedures. The Realm Health Literacy Test will be administered to ensure that participants are free of cognitive impairment that would...
  • Pregnancy. Inclusion/exclusion criteria will be verified using the screening tool in combination with review of participants' medical records

The study team makes the final eligibility decision.

Where it is enrolling

  • Miami, Florida, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 19 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Miami, Florida, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.